{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:27:17Z","timestamp":1792124837534,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004434","name":"Universit\u00e0 degli Studi di Firenze","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Mepolizumab was recently approved for treating Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) unresponsive to standard treatment or recurring after endoscopic sinus surgery (ESS). To date, few studies have assessed Mepolizumab\u2019s efficacy in severe type-2 CRSwNP. Our study aimed to analyze sinonasal outcomes in type-2 CRSwNP patients treated with 100\u00a0mg Mepolizumab administered subcutaneously every four weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective study of patients with severe, recalcitrant CRSwNP treated with Mepolizumab. Demographic and clinical characteristics were collected, including age, sex, and comorbidities such as asthma, nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (NERD), and allergic rhinitis (AR), as well as the number of previous ESS procedures and the interval since the last one. Patients were evaluated at baseline and after one year for blood eosinophil count, nasal polyp score (NPS), modified Lund-Kennedy score (mLKS), olfactory function (using a VAS scale and a 16-item Sniffin\u2019 identification test), SNOT-22, and sinus opacification on CT scans. The need for rescue ESS or systemic corticosteroids (SCS), response to treatment, and side effects were also recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data from 27 patients were collected. After one year, all scores showed significant improvement. NERD was the only factor associated with a less favorable improvement in olfactory function. There were no side effects reported, although 2 patients discontinued Mepolizumab as they were considered \u201cnon-responders.\u201d<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Mepolizumab is safe and effective in reducing the clinical, endoscopic, and radiological burden of disease, as well as in decreasing the need for salvage ESS or systemic steroids.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00405-024-09027-8","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T10:52:20Z","timestamp":1728989540000},"page":"265-272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Effects of Mepolizumab in the treatment of type 2 CRSwNP: a real-life clinical study"],"prefix":"10.1007","volume":"282","author":[{"given":"Pietro","family":"Orlando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Vivarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Minzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8124-3607","authenticated-orcid":false,"given":"Giuseppe","family":"Licci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Accinno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Brugnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Matucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vultaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2741-4460","authenticated-orcid":false,"given":"Giandomenico","family":"Maggiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"issue":"12","key":"9027_CR1","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1182\/blood.V79.12.3101.bloodjournal79123101","volume":"15","author":"CJ Sanderson","year":"1992","unstructured":"Sanderson CJ (1992) Interleukin-5, eosinophils, and disease. Blood 15(12):3101\u20133109","journal-title":"Blood"},{"issue":"5","key":"9027_CR2","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","volume":"128","author":"P Gevaert","year":"2011","unstructured":"Gevaert P, Van Bruaene N, Cattaert T et al (2011) Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol 128(5):989\u2013 \u2013\u200995.e1-8","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"9027_CR3","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa070812","volume":"20","author":"ME Rothenberg","year":"2008","unstructured":"Rothenberg ME, Klion AD, Roufosse FE et al (2008) Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 20(12):1215\u20131228","journal-title":"N Engl J Med"},{"issue":"20","key":"9027_CR4","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"18","author":"ME Wechsler","year":"2017","unstructured":"Wechsler ME, Akuthota P, Jayne D et al (2017) Mepolizumab or Placebo for Eosinophilic granulomatosis with Polyangiitis. N Engl J Med 18(20):1921\u20131932","journal-title":"N Engl J Med"},{"issue":"10","key":"9027_CR5","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1056\/NEJMoa0808991","volume":"5","author":"P Haldar","year":"2009","unstructured":"Haldar P, Brightling CE, Hargadon B et al (2009) Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 5(10):973\u2013984","journal-title":"N Engl J Med"},{"key":"9027_CR6","unstructured":"European Medicines Agency (2021) Mepolizumab summary of product characteristics.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nucala-epar-product-information_en.pdf accessed March 30 2024)"},{"key":"9027_CR7","unstructured":"GlaxoSmithKline (2021) Mepolizumab prescribing information. https:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Nucala\/pdf\/NUCALA-PI-PIL-IFU-COMBINED.PDF accessed March 30, 2024)"},{"issue":"10","key":"9027_CR8","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","volume":"9","author":"JK Han","year":"2021","unstructured":"Han JK, Bachert C, Fokkens W et al (2021) Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 9(10):1141\u20131153","journal-title":"Lancet Respir Med"},{"issue":"Suppl S29","key":"9027_CR9","first-page":"1","volume":"58","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens WJ, Lund VJ, Hopkins C et al (2020) European position paper on Rhinosinusitis and nasal polyps 2020. Rhinology 58(Suppl S29):1\u2013464","journal-title":"Rhinology"},{"key":"9027_CR10","unstructured":"https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2023-03-01&atto.codiceRedazionale=23A01126&elenco30giorni=false (2021, accessed March 30, 2024)"},{"key":"9027_CR11","doi-asserted-by":"crossref","unstructured":"Hopkins C, Gillett S, Slack R et al (200) Psychometric validity of the 22-item Sinonasal Outcome Test. Clin Otolaryngol 34(5):447\u2013454","DOI":"10.1111\/j.1749-4486.2009.01995.x"},{"issue":"5 Suppl","key":"9027_CR12","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/j.jaci.2006.09.005","volume":"118","author":"EO Meltzer","year":"2006","unstructured":"Meltzer EO, Hamilos DL, Hadley JA et al (2006) Rhinosinusitis: developing guidance for clinical trials. J Allergy Clin Immunol 118(5 Suppl):S17\u201361","journal-title":"J Allergy Clin Immunol"},{"key":"9027_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/000348949510410s02","volume":"167","author":"VJ Lund","year":"1995","unstructured":"Lund VJ, Kennedy DW (1995) Quantification for staging sinusitis. The staging and Therapy Group. Ann Otol Rhinol Laryngol Suppl 167:17\u201321","journal-title":"Ann Otol Rhinol Laryngol Suppl"},{"issue":"3","key":"9027_CR14","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00405-018-5248-1","volume":"276","author":"A Oleszkiewicz","year":"2019","unstructured":"Oleszkiewicz A, Schriever VA, Croy I et al (2019) Updated Sniffin\u2019 sticks normative data based on an extended sample of 9139 subjects. Eur Arch Otorhinolaryngol 276(3):719\u2013728","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"4","key":"9027_CR15","first-page":"183","volume":"31","author":"VJ Lund","year":"1993","unstructured":"Lund VJ, Mackay IS (1993) Staging in rhinosinusitus. Rhinology 31(4):183\u2013184","journal-title":"Rhinology"},{"issue":"1","key":"9027_CR16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","volume":"113","author":"RA Nathan","year":"2004","unstructured":"Nathan RA, Sorkness CA, Kosinski M et al (2004) Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 113(1):59\u201365","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"9027_CR17","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1034\/j.1399-3003.1999.14d29.x","volume":"14","author":"EF Juniper","year":"1999","unstructured":"Juniper EF, O\u2019Byrne PM, Guyatt GH et al (1999) Development and validation of a questionnaire to measure asthma control. Eur Respir J 14(4):902\u2013907","journal-title":"Eur Respir J"},{"issue":"2","key":"9027_CR18","first-page":"126","volume":"58","author":"L Zhang","year":"2020","unstructured":"Zhang L, Zhang Y, Gao Y et al (2020) Long-term outcomes of different endoscopic sinus surgery in recurrent chronic rhinosinusitis with nasal polyps and asthma. Rhinology 58(2):126\u2013135","journal-title":"Rhinology"},{"issue":"1","key":"9027_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12016-021-08844-7","volume":"62","author":"T Vanderhaegen","year":"2022","unstructured":"Vanderhaegen T, Gengler I, Dendooven A et al (2022) Eosinophils in the field of nasal polyposis: towards a better understanding of Biologic therapies. Clin Rev Allergy Immunol 62(1):90\u2013102","journal-title":"Clin Rev Allergy Immunol"},{"key":"9027_CR20","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3389\/fimmu.2016.00475","volume":"7","author":"F Imamura","year":"2016","unstructured":"Imamura F, Hasegawa-Ishii S (2016) Environmental toxicants-Induced Immune responses in the olfactory mucosa. Front Immunol 7:475","journal-title":"Front Immunol"},{"issue":"12","key":"9027_CR21","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1111\/all.15909","volume":"78","author":"A Vultaggio","year":"2023","unstructured":"Vultaggio A, Accinno M, Vivarelli E et al (2023) Blood CD62Llow inflammatory eosinophils are related to the severity of asthma and reduced by mepolizumab. Allergy 78(12):3154\u20133165","journal-title":"Allergy"},{"key":"9027_CR22","doi-asserted-by":"publisher","first-page":"175346662110093","DOI":"10.1177\/17534666211009398","volume":"15","author":"A Detoraki","year":"2021","unstructured":"Detoraki A, Tremante E, D\u2019Amato M et al (2021) Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study. Ther Adv Respir Dis 15:17534666211009398","journal-title":"Ther Adv Respir Dis"},{"issue":"9","key":"9027_CR23","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.3390\/biomedicines11092424","volume":"11","author":"D Bagnasco","year":"2023","unstructured":"Bagnasco D, Nicola S, Testino E et al (2023) Long-term efficacy of Mepolizumab at 3 years in patients with severe asthma: comparison with clinical trials and Super responders. Biomedicines 11(9):2424","journal-title":"Biomedicines"},{"issue":"2","key":"9027_CR24","doi-asserted-by":"publisher","first-page":"100746","DOI":"10.1016\/j.waojou.2023.100746","volume":"16","author":"U F\u00f6rster-Ruhrmann","year":"2023","unstructured":"F\u00f6rster-Ruhrmann U, Stergioudi D, Szczepek AJ et al (2023) A real-life comparison of pulmonary and nasal outcomes in patients with severe asthma and nasal polyposis treated with T2-biologics. World Allergy Organ J 16(2):100746","journal-title":"World Allergy Organ J"},{"issue":"8","key":"9027_CR25","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3390\/jpm12081304","volume":"12","author":"S Gallo","year":"2022","unstructured":"Gallo S, Castelnuovo P, Spirito L et al (2022) Mepolizumab improves outcomes of chronic rhinosinusitis with nasal polyps in severe asthmatic patients: a Multicentric Real-Life Study. J Pers Med 12(8):1304","journal-title":"J Pers Med"},{"issue":"2","key":"9027_CR26","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3390\/biomedicines11020485","volume":"11","author":"MS Dom\u00ednguez-Sosa","year":"2023","unstructured":"Dom\u00ednguez-Sosa MS, Cabrera-Ram\u00edrez MS, Marrero-Ramos MDC et al (2023) Real-life effectiveness of Mepolizumab in Refractory Chronic Rhinosinusitis with nasal polyps. Biomedicines 11(2):485","journal-title":"Biomedicines"},{"issue":"1","key":"9027_CR27","first-page":"37","volume":"17","author":"B Barroso","year":"2023","unstructured":"Barroso B, Valverde-Monge M, Alobid I et al (2023) Improvement in olfaction in patients with CRSwNP and severe asthma taking Anti-IgE and Anti-IL-5 biologics: a real-life study. J Investig Allergol Clin Immunol 17(1):37\u201344","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"6","key":"9027_CR28","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.jaci.2020.02.035","volume":"145","author":"KM Buchheit","year":"2020","unstructured":"Buchheit KM, Dwyer DF, Ordovas-Montanes J et al (2020) IL-5R\u03b1 marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 145(6):1574\u20131584","journal-title":"J Allergy Clin Immunol"},{"key":"9027_CR29","doi-asserted-by":"crossref","unstructured":"Boesveldt S, Postma EM, Boak D et al Anosmia-A Clin Rev Chem Senses. 2017 1;42(7):513\u2013523","DOI":"10.1093\/chemse\/bjx025"},{"key":"9027_CR30","doi-asserted-by":"publisher","first-page":"117005","DOI":"10.1016\/j.neuroimage.2020.117005","volume":"218","author":"MG Peter","year":"2020","unstructured":"Peter MG, M\u00e5rtensson G, Postma EM et al (2020) Morphological changes in secondary, but not primary, sensory cortex in individuals with life-long olfactory sensory deprivation. NeuroImage 218:117005","journal-title":"NeuroImage"},{"issue":"6","key":"9027_CR31","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/alr.21922","volume":"7","author":"P Han","year":"2017","unstructured":"Han P, Whitcroft KL, Fischer J et al (2017) Olfactory brain gray matter volume reduction in patients with chronic rhinosinusitis. Int Forum Allergy Rhinol 7(6):551\u2013556","journal-title":"Int Forum Allergy Rhinol"},{"issue":"3","key":"9027_CR32","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s00405-023-08309-x","volume":"281","author":"P Orlando","year":"2024","unstructured":"Orlando P, Licci G, Kuitche D et al (2024) Effectiveness of dupilumab versus endoscopic sinus surgery for the treatment of type-2 chronic rhinosinusitis with nasal polyps: a preliminary report. Eur Arch Otorhinolaryngol 281(3):1317\u20131324","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"7","key":"9027_CR33","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1097\/00005537-200007000-00001","volume":"110","author":"RC Kern","year":"2000","unstructured":"Kern RC (2000) Chronic sinusitis and anosmia: pathologic changes in the olfactory mucosa. Laryngoscope 110(7):1071\u20131077","journal-title":"Laryngoscope"},{"issue":"1","key":"9027_CR34","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12890-023-02415-6","volume":"23","author":"I Suzaki","year":"2023","unstructured":"Suzaki I, Tanaka A, Yanai R et al (2023) Eosinophilic granulomatosis with polyangiitis developed after dupilumab administration in patients with eosinophilic chronic rhinosinusitis and asthma: a case report. BMC Pulm Med 23(1):130","journal-title":"BMC Pulm Med"},{"issue":"10","key":"9027_CR35","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","volume":"10","author":"ME Wechsler","year":"2022","unstructured":"Wechsler ME, Klion AD, Paggiaro P et al (2022) Effect of Dupilumab on Blood Eosinophil counts in patients with asthma, chronic Rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis. J Allergy Clin Immunol Pract 10(10):2695\u20132709","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-024-09027-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-024-09027-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-024-09027-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T14:55:20Z","timestamp":1736952920000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-024-09027-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["9027"],"URL":"https:\/\/doi.org\/10.1007\/s00405-024-09027-8","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]},"assertion":[{"value":"2 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}